How the AI revolution can accelerate early drug discovery
Rob Scoffin and Matthew Habgood from solutions provider Cresset look to the future of drug discovery and the roles that artificial intelligence and machine learning could play.
List view / Grid view
Articles
Advanced 3D cell-based technologies
Recent regulatory changes in the US and Europe are driving the adoption of advanced 3D cell-based technologies, such as organoids and organ-on-chips, in drug development, replacing traditional animal testing and offering safer, cost-effective alternatives.
Scientists target protein in skeletal muscle composition
A group of researchers from Tokyo Metropolitan University have illuminated a crucial piece of the intricate puzzle surrounding the regulation of muscle mass and metabolic processes within skeletal muscle.
Drug Target Review – Issue 3 2023
A new Drug Target Review issue is now ready to download! This issue features articles on vaccine development, artificial intelligence and organoids.
Bioengineered instrument reveals hidden cancer cells
Scientists at Stanford University have engineered a biomolecule that can specifically remove mucins from cancer cells. This breakthrough could have a significant impact on future cancer therapies.
New research holds significance in regulating T cell function
New research shows T cells use the nuclear receptor RARα not just for gene regulation, but also to trigger cell surface events that activate them against pathogens and cancer.
Innovative leukaemia treatment with tcxpress platform
BlueSphere Bio's TCXpress platform revolutionises the isolation and functional characterisation of T-cell receptors (TCRs) with unparalleled speed and efficiency, enabling rapid identification of unique TCRs from thousands of individual T cells within days.
Brain macrophage in Parkinson’s disease neuroinflammation
A growing body of evidence pinpoints neuroinflammation as a pivotal factor driving brain-related pathogenesis. Yet, a crucial question lingers: among the various immune cell groups residing within the brain, which one orchestrates this inflammatory reaction?
Addressing increasingly resistant drugs by infectious agents
Infectious agents' drug resistance is a complex challenge affecting survival. Understanding their mechanisms in vectors, the potential of plant-derived treatments, and roles of nucleic acids and biochemical compounds is crucial for effective therapy, requiring collaborative international research through the One Health Initiative.
Decoding cell therapy variants with Dr Andy Bader
The field of cell therapy has emerged as a beacon of hope, promising transformative treatments for various diseases. Diving into the intricacies of this domain, this exclusive interview explores the distinctions between two key approaches – autologous and allogeneic cell therapies. We look at the nuances of cell sourcing, preclinical…
Stem cell therapy: Alzheimer’s disease symptoms
In the pursuit of a remedy for Alzheimer's disease, a frontier in medical science is illuminating a glimmer of hope. Stem cell therapies have already demonstrated their prowess in treating diverse cancers and ailments linked to the blood and immune system.
Drug Discovery Article Competition Winner
We are thrilled to announce the winner of the Drug Target Review x ELRIG's Article Competition: Dr Rosa Woldegebriel, Lead Scientist at the Human Centric Drug Discovery in Oxford, UK, whose article titled "Advancing Drug Discovery for Pain Disorders: Human iPSC-Based Approach" presents a revolutionary method in pharmaceutical research. Addressing…
Women in Stem with Theonie Anastassiadis
Join us for our monthly Women in STEM series where we showcase and celebrate the achievements of inspiring women in the field. This month we interview Theonie Anastassiadis, Cofounder & Chief Innovation Officer of Alltrna and Senior Principal of Flagship Pioneering. As a senior principal at Flagship Pioneering, Theonie conceives,…
Therapeutic frontiers: the potential of RRx-001 and AdAPT-001
Meet RRx-001 (nibrozetone) and AdAPT-001—two cutting-edge compounds crafted by EpicentRx. In this Q&A session with Dr Bryan Oronsky, Chief Development Officer at EpicentRx, we discover novel mechanisms, diverse applications, and game-changing impact on cancer treatment and beyond.
Cancer immunotherapy: GDF-15’s role in Anti-PD-1 resistance
In this interview with Christine Schuberth-Wagner, Chief Scientific Officer at CatalYm, we discover research uncovering a central factor contributing to anti-PD-1 resistance in cancer immunotherapy.